Shares of Ovid Therapeutics Inc (NASDAQ:OVID) have been assigned a consensus rating of “Buy” from the six research firms that are presently covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating and five have issued a buy rating on the company. The average twelve-month price objective among brokers that have issued ratings on the stock in the last year is $19.33.
Several equities research analysts recently weighed in on OVID shares. Zacks Investment Research upgraded shares of Ovid Therapeutics from a “hold” rating to a “buy” rating and set a $11.00 target price for the company in a research note on Thursday, November 16th. ValuEngine upgraded shares of Ovid Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Sunday, December 31st.
Shares of Ovid Therapeutics (OVID) opened at $8.90 on Thursday. Ovid Therapeutics has a one year low of $5.28 and a one year high of $15.93.
Ovid Therapeutics (NASDAQ:OVID) last released its earnings results on Thursday, November 9th. The company reported ($0.38) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.54) by $0.16. research analysts expect that Ovid Therapeutics will post -4.08 earnings per share for the current fiscal year.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Bank of New York Mellon Corp bought a new stake in shares of Ovid Therapeutics in the second quarter valued at about $135,000. TIAA CREF Investment Management LLC bought a new stake in shares of Ovid Therapeutics in the second quarter valued at about $142,000. Schwab Charles Investment Management Inc. bought a new stake in shares of Ovid Therapeutics in the second quarter valued at about $153,000. OxFORD Asset Management LLP bought a new position in Ovid Therapeutics during the second quarter worth about $189,000. Finally, Citadel Advisors LLC bought a new position in Ovid Therapeutics during the second quarter worth about $204,000. Institutional investors and hedge funds own 29.36% of the company’s stock.
COPYRIGHT VIOLATION WARNING: “Brokerages Set Ovid Therapeutics Inc (OVID) PT at $19.33” was reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this news story on another domain, it was illegally copied and republished in violation of United States and international trademark & copyright law. The correct version of this news story can be read at https://www.dispatchtribunal.com/2018/02/19/brokerages-set-ovid-therapeutics-inc-ovid-pt-at-19-33.html.
Ovid Therapeutics Company Profile
Ovid Therapeutics Inc (Ovid) is a biopharmaceutical company. The Company is engaged in developing medicines for patients and families living with rare neurological disorders. Its lead drug candidate is OV101. The Company’s second lead drug candidate is OV935. OV101 (gaboxadol) is a delta-selective GABAA receptor agonist.
Receive News & Ratings for Ovid Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ovid Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.